TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38982000
Drug: Inhaled xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled xenon combined with target temperature management (33 °C) for 24 hours
Study: 38982051
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) chemotherapy
Study: 38982528
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin glargine 300 U/mL (Gla-300)
Study: 38982903
Drug: Treatment modality
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modality A
Study: 38982903
Drug: Treatment modality
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment modality B
Study: 38983151
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg orally twice daily until disease progression or unacceptable toxicity
Study: 38983158
Drug: Nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 20 mg administered before surgical incision and at the end of surgery during chest tube insertion.
Study: 38983158
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 100 mL administered as control.
Study: 38983729
Drug: Vilaprisan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (4 mg)
Study: 38983729
Drug: Vilaprisan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (2 mg)
Study: 38983729
Drug: Vilaprisan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (4 mg and 2 mg)
Study: 38983736
Drug: Corifollitropin α
Normalized name: urofollitropin
DrugBank: Urofollitropin (DB00094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corifollitropin α (weekly continuous dosing)
Study: 38983736
Drug: Daily follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily follicle-stimulating hormone protocol (control)
Study: 38984118
Drug: LCD supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCD supplement (lutein 20 mg, zeaxanthin isomers 4 mg, curcumin 200 mg, vitamin D3 600 IU)
Study: 38984118
Drug: LCD supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCD supplement
Study: 38985436
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg, orally, up to once daily for up to 52 weeks
Study: 38985561
Drug: Rezafungin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezafungin (400 mg/200 mg once-weekly)
Study: 38985561
Drug: Caspofungin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (70 mg/50 mg once-daily)
Study: 38985785
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin for 1-5 month-olds during trachoma MDA
Study: 38985817
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to post-treatment recommendations
Study: 38985979
Drug: LIS1 (0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIS1 (0.6, 1, 3, 6, 8, or 10 mg/kg)
Study: 38985979
Drug: LIS1 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIS1 (8 mg/kg and 10 mg/kg)
Study: 38986058
Drug: Nirsevimab therapy
Normalized name: Nirsevimab
DrugBank: Nirsevimab (DB16258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirsevimab therapy
Study: 38986421
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D)
Study: 38986421
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D) in group 1 + phase 1b RP2D
Study: 38986541
Drug: 0.1 mL
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL of 24% sucrose administered 2 min prior to painful procedures
Study: 38986608
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg HLX22 + HLX02 + XELOX (group A)
Study: 38986608
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg HLX22 + HLX02 + XELOX (group B)
Study: 38986667
Drug: Aldose reductase
Normalized name: Aldose reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldose reductase inhibitor
Study: 38986791
Drug: Common side
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common side effect treatments (acetaminophen, loperamide, ondansetron)
Study: 38986891
Drug: Placebo control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control, mock laser (ML) acupuncture
Study: 38986891
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (EA and ML)
Study: 38987228
Drug: Eculizumab (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (intravenous infusion, once weekly for 4 weeks) with IVIg treatment
Study: 38987228
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with IVIg treatment
Study: 38987363
Drug: Regorafenib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (120 or 160 mg daily) given from day 4 to day 10 of each 14-day cycle of FOLFIRINOX (including oxaliplatin, folinic acid, fluorouracil, and irinotecan at 150 or 180 mg/m²)
Study: 38987421
Drug: AMH ≥
Normalized name: Anti-Müllerian hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH ≥ 1.1 ng/mL
Study: 38987421
Drug: AMH <
Normalized name: Antimicrobial Handwashing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH < 1.1 ng/mL
Study: 38987784
Drug: Coenzyme-Q10 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme-Q10 (240 mg daily)
Study: 38987786
Drug: Combined usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined usage of povidone-iodine irrigation and topical vancomycin powder before wound closure
Study: 38988185
Drug: Govorestat 5
Normalized name: govorestat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Govorestat 5 mg/kg
Study: 38988185
Drug: Govorestat 20
Normalized name: govorestat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Govorestat 20 mg/kg
Study: 38988185
Drug: Govorestat 40
Normalized name: govorestat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Govorestat 40 mg/kg
Study: 38988285
Drug: ASC10 (50-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC10 (50-800 mg, twice daily for 5.5 days)
Study: 38989287
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (mannan-allergoid conjugates) via subcutaneous (SC) and sublingual (SL) routes at doses of 500, 1,000, 3,000, or 5,000 mTU/mL
Study: 38989287
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (mannan-allergoid conjugates) via SC
Study: 38989287
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (mannan-allergoid conjugates) via SL
Study: 38989414
Drug: PDS01ADC in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS01ADC in combination with floxuridine delivered via a hepatic artery infusion pump (HAIP)
Study: 38990016
Drug: GST-HG171; single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG171; single-dose administration; specific dosage not mentioned.
Study: 38990016
Drug: Healthy subjects;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects; single-dose administration of GST-HG171; specific dosage not mentioned.
Study: 38990090
Drug: Dostarlimab with
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab with chemotherapy
Study: 38990250
Drug: Conservative approach
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative approach (optimal medical therapy alone)
Study: 38990564
Drug: Ultralow-dose radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultralow-dose radiation therapy to 4 Gy in 2 fractions, with an additional 20 Gy in 10 fractions for persistent cases.
Study: 38990564
Drug: Ultralow-dose radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultralow-dose radiation therapy to 4 Gy in 2 fractions.
Study: 38990564
Drug: Ultralow-dose radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultralow-dose radiation therapy to 4 Gy in 2 fractions for newly diagnosed, untreated stage I mucosa-associated lymphoid tissue lymphoma.
Study: 38990638
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (COCP) users (n=20)
Study: 38990638
Drug: Hormonal implant
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal implant users (n=20)
Study: 38990638
Drug: Hormonal injection
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal injection users (n=20)
Study: 38990808
Drug: Social Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Cognitive Behaviour Treatment (SCBT)
Study: 38990927
Drug: ILB® (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILB® (low molecular weight dextran sulphate) administered at a dosage of 2 mg/kg weekly for up to 38 weeks
Study: 38990927
Drug: ILB® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILB® treatment
Study: 38990927
Drug: Long-term follow-up
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term follow-up after ILB® treatment
Study: 38991123
Drug: Tipifarnib 300
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib 300 mg orally twice daily for 21 days in a 28-day cycle
Study: 38991137
Drug: Pfizer-BioNTech vaccine
Normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer-BioNTech vaccine (2 doses)
Study: 38991216
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with oxygen during acute SARS-CoV-2 infection
Study: 38991671
Drug: Experiencing medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiencing medication side effects.
Study: 38991671
Drug: Contextual factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contextual factors such as frequent changes to prescription and polypharmacy.
Study: 38991714
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 0.2% + 2 µg/mL epinephrine
Study: 38991714
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine 0.2% + 5 µg/mL epinephrine
Study: 38992025
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of protein levels and rs6770663
Study: 38992490
Drug: BEC change
Normalized name: racepinephrine
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEC change during ICS treatment
Study: 38993008
Drug: Soticlestat (TAK-935)
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat (TAK-935) 300 mg single oral dose
Study: 38993026
Drug: Avacopan 30
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan 30 mg single oral dose in patients with mild hepatic impairment
Study: 38993026
Drug: Avacopan 30
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan 30 mg single oral dose in patients with moderate hepatic impairment
Study: 38993150
Drug: SAR442085 (5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR442085 (5-7.5 mg/kg)
Study: 38993983
Drug: Once-weekly HIIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly HIIT (75 min, 16 weeks)
Study: 38993983
Drug: Thrice-weekly HIIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly HIIT (75 min, 16 weeks)
Study: 38994348
Drug: MDMA-assisted brief
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted brief cognitive behavioral conjoint therapy (bCBCT)
Study: 38994833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stool tests with alarm features
Study: 38995311
Drug: Vimseltinib, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vimseltinib, 30 mg twice weekly
Study: 38995504
Drug: 1.5% ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% ruxolitinib cream (continuous-use)
Study: 38995504
Drug: 1.5% ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% ruxolitinib cream (as-needed use)
Study: 39420169
Drug: TAK-003 (live-attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 (live-attenuated tetravalent dengue vaccine)
Study: 38996463
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose of CAR22
Study: 38996972
Drug: 1HP (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1HP (daily rifapentine plus isoniazid for 28 days)
Study: 38996972
Drug: 3HP (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP (weekly rifapentine plus isoniazid for 3 months)
Study: 38997229
Drug: Clay-based Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clay-based Traditional Medicine (TM) use (34% of participants)
Study: 38997279
Drug: Gut microbiota-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut microbiota-based machine learning (ML) algorithms for ALD diagnosis
Study: 38997279
Drug: Gut microbiota-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut microbiota-based machine learning (ML) algorithms for MASLD diagnosis
Study: 38997279
Drug: Gut microbiota-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut microbiota-based machine learning (ML) algorithms for ALD and MASLD external validation
Study: 38997607
Drug: Deep brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep brain stimulation (DBS) therapy
Study: 38997684
Drug: Personalized visualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized visualized oral health education combined with conventional oral hygiene education
Study: 38997684
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene education only
Study: 39001374
Drug: Alpha DaRT
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha DaRT treatment
Study: 39001413
Drug: Clinical and
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and biological samples collection
Study: 39001621
Drug: Bismuth-metronidazole-tetracycline and
Normalized name: bismuth subcitrate, tetracycline and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies
Study: 39001621
Drug: Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole
Study: 39001621
Drug: Sequential clarithromycin-amoxicillin-tinidazole/metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential clarithromycin-amoxicillin-tinidazole/metronidazole
Study: 39001621
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effectiveness by indication
Study: 39001864
Drug: Jewel patch
Normalized name: jewel weed whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jewel patch wearable cardioverter-defibrillator (P-WCD) delivering a single shock of 150 J
Study: 39002122
Drug: TCK-276 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCK-276 25 mg/day
Study: 39002122
Drug: TCK-276 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCK-276 75 mg/day
Study: 39002122
Drug: TCK-276 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCK-276 175 mg/day
Study: 39002551
Drug: Ruxolitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (10 mg twice daily for ages 12-18, 5 mg twice daily for ages 6-12, 4 mg/m² for ages 2-6)
Study: 39002641
Drug: Pemvidutide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemvidutide treatment
Study: 39003182
Drug: Trifluridine/tipiracil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil administered concomitantly to radiotherapy
Study: 39003185
Drug: Neoadjuvant durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant durvalumab plus platinum-based chemotherapy (D+CT) followed by adjuvant durvalumab
Study: 39003306
Drug: Somatic mutations
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatic mutations (e.g., TP53, CDH1, PTEN)
Study: 39004096
Drug: H3N2 M2SR
Normalized name: Haemagglutinin-strain A(H3N2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3N2 M2SR vaccine plus Fluzone HD (n=94)
Study: 39004096
Drug: H3N2 M2SR
Normalized name: Haemagglutinin-strain A(H3N2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3N2 M2SR vaccine plus placebo (n=89)
Study: 39004217
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion for 48 hours to maintain HR at 60 to 90 beats/min
Study: 39004432
Drug: ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ixekizumab (IXE) 80 mg every 4 weeks
Study: 39004434
Drug: BCG-Denmark vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-Denmark vaccine (0.05 mL intradermal dose)
Study: 39004647
Drug: SHR-A1811 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 at 4.8 mg/kg
Study: 39004647
Drug: SHR-A1811 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 at 8.0 mg/kg
Study: 39004647
Drug: SHR-A1811 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 at 6.4 mg/kg
Study: 39004848
Drug: Chronic drug
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic drug abuse
Study: 39005691
Drug: Debulking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debulking therapy (including rituximab-containing immunochemotherapy regimens and radiotherapy)
Study: 39005691
Drug: Axi-cel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axi-cel treatment
Study: 39006315
Drug: RBL (REBYOTA®)
Normalized name: Rebyota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBL (REBYOTA®) administration after non-CDI antibiotic use
Study: 39006315
Drug: High-risk antibiotics
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk antibiotics
Study: 39006430
Drug: Fluorometholone 0.1%
Normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorometholone 0.1% eyedrops twice daily for four weeks
Study: 39007062
Drug: Mogamulizumab treatment
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mogamulizumab treatment
Study: 39007065
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m² combined with cyclophosphamide and vincristine (VPC)
Study: 39007065
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m²
Study: 39007063
Drug: Tuberculosis treatment
Normalized name: Hydrazides for tuberculosis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis treatment decision algorithms (TDAs)
Study: 39007556
Drug: Emergency mechanical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency mechanical reperfusion (EMR) treatment
Study: 39007703
Drug: Trauma-Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused Cognitive Behavioral Therapy combined with Cognitive-Behavioral Therapy for eating disorders (TF-CBT-WB)
Study: 39007830
Drug: Dual antithrombotic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antithrombotic therapy (DAT; OAC plus P2Y12 inhibitor)
Study: 39007942
Drug: Low IFN-γ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low IFN-γ, TNF and IL-1β before treatment (Arm 2)
Study: 39007942
Drug: Arm 1
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1 treatment in patients with low IFN-γ production at D0
Study: 39008067
Drug: Rechallenge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rechallenge of RLT (Radioligand Therapy)
Study: 39008236
Drug: Tirzepatide (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (pooled doses of 5, 10, and 15 mg)
Study: 39008481
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) and WT1/DC vaccination (8-10 x 106 cells/vaccination) in combination with standard-of-care chemotherapy (cisplatinum 75mg/m2 and pemetrexed 500mg/m2)
Study: 39008542
Drug: Cladribine (CLAD)
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine (CLAD) tablets
Study: 39008999
Drug: Emtricitabine plus
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine plus tenofovir alafenamide (200/300 mg)
Study: 39008999
Drug: Emtricitabine plus
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine plus tenofovir disoproxil fumarate (200/25 mg)
Study: 39009085
Drug: Bulevirtide 2
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Bulevirtide 2 mg/day
Study: 39009085
Drug: Bulevirtide 10
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Bulevirtide 10 mg/day
Study: 39009116
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein > 2 mg/l